Bandera A1, Cazorla O2, Perez-Villa L3, García-Anaya MJ4, Alvarez M5*, Toledo I4, Medina JA4 and Gómez-Millán J4
1Department of Otorhinolaryngology, Agencia Sanitaria Costa del Sol., Spain
2Department of Otorhinolaryngology, Instituto de investigaciones biomédicas de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, Spain
3Department of Pathology, Instituto de investigaciones biomédicas de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, Spain
4Department of Radiation Oncology, Instituto de investigaciones Biomédicas de Malaga (IBIMA), Hospital Universitario Virgen de la Victoria, Spain
5Department of Pathology, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA) Spain
Background: DNA topoisomerase has an essential role in cell division.
Aims: We investigated the role of Topoisomerase-2A as a prognostic biomarker in nasopharynx carcinoma.
Study Design: Retrospective cohort study.
Methods: We retrospectively reviewed 58 with nasopharynx cancer. Immunohistochemistry was performed and a validated score was calculated. The role of TOPO2A as a survival prognostic factor was studied.
Results: Topo2A expression was inversely correlated with stage, presenting early stage a 35.6% expression compared with 76.9% in advance stage (p=0.01). In the logistic regression analysis, stage (HR 7.94; 0.01 to 0.46; p=0.02) and age (HR 0.26; 0.08 to 0.92; p=0.04) were independently associated with TOPO2A expression. Patients with topoisomerase expression presented a significant decrease in OS (p=0.05) and PFS (p=0.03). In the Cox regression analysis for OS and PFS, the prognostic value of TOPO2A was confirmed.
Conclusion: Topoisomerase-2A expression may identify a subgroup of patients with worse prognosis in which new molecular therapies, or chemotherapy intensification could be tested.
Topo2A; Nasopharynx; Radiotherapy; Chemotherapy
Bandera A, Cazorla O, Perez-Villa L, García-Anaya MJ, Alvarez M, Toledo I, et al. The Role of Topoisomerase (TOPO2A) as Prognostic Factor in Nasopharyngeal Carcinoma. Am J Otolaryngol Head Neck Surg. 2022;5(1): 1171..